Cancer Breakthrough Technology
Cancer treatment outcomes have significantly improved over the past decade associated with the discovery and advancement of cytotoxic, targeted and immunotherapies. Recent progress in the understanding of the biology of cancer now permits rational treatment selection for individual patients with additional, and significant, impact on survival.
The Fund offers selected investment opportunities directed at the provision of individual patient-directed treatment in oncology. These opportunities are de-risked, asset-based investments in transformative, disruptive, and high return technologies associated with the fight against cancer. The investment has a priority position backed by independently valued IP and patents valued at many times the sums invested.
- Prospective Investor Information Form
- Investor Application Pack
- DiaTech TPA Brochure – CEER
- Diatech MiCK Brochure
- Cancer Advances VACCICURE Brochure
- Fund Prelaunch
- Fund Fact sheet